Activation of the Raf/MEK/ERK pathway, often by gainof-function mutations of RAS or RAF, is observed in many human cancers. The extracellular signal-regulated kinase (ERK) pathway is required for the proliferation of cancer cell lines harboring activating BRAF or, to a lesser extent, activating RAS mutations. It is still unclear, however, whether the pathway is required in vivo for tumor development, particularly in tumors in which B-Raf is not mutationally activated. During embryonic development, B-Raf is essential for angiogenesis in the placenta. To address the question of whether B-Raf contributed to tumor angiogenesis in vivo we conditionally ablated B-Raf in a model of pancreatic islet carcinoma driven by the functional inactivation of tumor suppressors (RIP1Tag2), which critically depends on angiogenesis for growth. We find that B-Raf is dispensable for the proliferation of tumor cells in culture, but necessary for ERK activation and for the expression of angiogenic factors by tumor cells in vivo and in vitro. In vivo, these defects result in the formation of hollow tumors with decreased vessel density and strongly reduced proliferation. The progression from adenoma to carcinoma is also significantly impaired. Thus, endogenous B-Raf contributes to the development of RIP1Tag2 tumors by supporting the stromal response and tumor progression.
Introduction
The extracellular signal-regulated kinase (ERK) pathway translates extracellular signals in a variety of physiological outcomes such as cell proliferation, survival and migration. Typically, the cascade is initiated by Ras, which recruits Raf from the cytosol to the cell membrane, where activation occurs (Wellbrock et al., 2004) . Raf binds and activates the dual specificity kinase MAPK (mitogen-activated protein kinase)/ERK kinase (MEK), which in turn phosphorylates ERK on activating threonine and tyrosine residues. An impressive range of substrates, including proteins involved in cell proliferation, survival and motility, has been attributed to activated ERK mainly by in-vitro studies. Constitutive ERK activation has often been associated with transformation in experimental systems and is observed in human cancers, where it can be due to gain-of-function mutations in tyrosine kinase receptor genes or in its more direct upstream regulators, RAS and BRAF (Garnett and Marais, 2004; Downward, 2006) . ERK activation is required for the proliferation of melanoma cells bearing an activating BRAF mutation. In contrast, cells with activating NRAS mutations are much less sensitive to ERK inhibition, indicating that other targets might be more important in this setting (Solit et al., 2006) . Thus, it is at present unclear whether activation of the ERK pathway is required for proliferation or for other aspects of tumor progression, in particular in tumors in which BRaf is not mutationally activated.
Mammals express three Raf kinases, A-Raf, B-Raf and c-Raf-1. B-Raf is most similar to the Rafs of lower organisms, it interacts best with both Ras and MEK, has the highest basal kinase activity (Emuss et al., 2005) and is most readily activated by extracellular stimuli (Wellbrock et al., 2004) . In contrast to c-Raf-1 (Galabova- Kovacs et al., 2006a) , B-Raf is indispensable for MEK/ERK activation in cultured mouse fibroblasts and in the placenta, but not in the embryo proper, during development. Intriguingly, B-Raf sustains placental development not by mediating cell proliferation or survival, but rather by regulating the production of vascular endothelial growth factor A (VEGF-A, Galabova-Kovacs et al., 2006b), a prototype angiogenic factor with a prominent role in tumor-induced neovascularization (Ferrara et al., 2003) .
Tumors organize their own oxygen and nutrient supply by inducing quiescent endothelia to proliferate. This 'angiogenic switch' allows them to develop into macroscopic lesions and is therefore a critical step in tumor progression. The RIP1Tag2 mouse model of pancreatic islet carcinoma has been extensively used to document the importance of tumor-induced angiogenesis, to investigate its underlying mechanisms (Bergers et al., 2000; Inoue et al., 2002; Nozawa et al., 2006) , and to test the efficacy of antiangiogenic therapies (Bergers et al., 1999; Casanovas et al., 2005) . In RIP1Tag2 transgenic mice, the rat insulin gene promoter drives the expression of simian virus 40 large T antigen (SV40T) in b cells, causing the inactivation of the tumor suppressors p53 and pRb (Hanahan, 1985; Herzig et al., 1999) . Islet hyperplasia/dysplasia is detectable around 5 weeks of age. About 25% of the hyperplastic islets switch on angiogenesis by 9 weeks, and a subset progresses to solid tumors. VEGF-A is essential for this angiogenic switch (Bergers et al., 1999; Compagni et al., 2000; Inoue et al., 2002) , and inhibition of VEGF-A production or signaling represses tumor outgrowth. The probability of Ras pathway activation in tumors dependent on the loss of Rb is low (Bild et al., 2006) . Therefore, B-Raf and the ERK pathway, as Ras subeffectors, are not necessarily expected to be essential for tumor development in the RIP1Tag2 model. Here, we show that b-cellrestricted B-Raf ablation delays progression of the RIP1Tag2 tumors and reduces neovascularization, the recruitment of stromal cells and matrix deposition. As a molecular correlate, ERK phosphorylation and the expression of the ERK downstream target Egr-1 are reduced in B-Raf-deficient tumors in vivo and in tumorderived cell lines in vitro, leading to decreased transcription of the Egr-1 target genes transforming growth factor-b (TGF-b) and collagen type I. Impaired phosphorylation of the indirect ERK targets eIF4E and of its inhibitor 4E-BP1, which control the translation of cancer-related mRNAs, correlates with reduced expression of the VEGF-A protein. These data reveal that endogenous B-Raf and the ERK pathway can support tumor development in a paracrine manner, by eliciting a stromal response in tumors in which the BRaf/ERK pathway is not mutationally activated.
Results and discussion
B-Raf ablation affects tumor development in RIP1Tag2 mice RIP-Cre;b-raf f/f mice (BbKO, B-Raf deleted in b cells) were generated by mating the RIP-Cre mouse strain (Ahlgren et al., 1998) with a b-raf f/f line (Chen et al., 2006; Galabova-Kovacs et al., 2006b) . Partial conversion of the b-raf flox to the b-raf D allele was observed in pancreata from these mice, but not in other organs (Figure 1a) . The partial conversion observed is due to the presence in the pancreata of cell types other than b cells, in which deletion does not occur. Indeed, immunohistochemical analysis of wild-type (WT) pancreata revealed that B-Raf was uniformly expressed in endocrine islets (composed of a, b, d, e and PP cells). BRaf was absent, however, from the central portion of BbKO islets, occupied by the b cells (Figure 1b) . BbKO mice were viable, fertile and healthy. Islet morphology, vascularization and VEGF-A expression did not significantly differ from WT (data not shown). Thus, B-Raf is not essential for islet development and homeostasis. In addition, ERK phosphorylation could be uniformly detected by immunohistochemistry in BbKO islets (Figure 1c) . Taking into account the consistent lack of B-Raf expression in the b-cell-enriched area of BbKO islets (Figure 1b) , we have no reason to assume that the ERK phosphorylation observed may be due to inefficient b-raf deletion. In the absence of a satisfactory double-staining protocol, however, we cannot formally prove that B-Raf is not expressed in the pERK þ islet cells. With this caveat, our results are consistent with previous findings indicating that ERK phosphorylation induced by b-cell agonists such as glucagon-like peptide is Raf independent (Gomez et al., 2002) .
To assess the role of B-Raf in islet carcinogenesis, we generated RIP1Tag2;BbKO double-transgenic mice. RIP1Tag2;BbKO mice survived longer than controls, although the median survival time did not significantly differ between the two groups ( Figure 2a RIP1Tag2;BbKO tumors developed less and smaller tumors than their control littermates, although this difference was not significant (Figure 2b) . However, the BbKO tumors could be readily distinguished from the WT tumors based on their deep red color and hemorrhagic appearance. The BbKO tumors contained a multitude of large, blood-filled lacunae. These lacunae are a characteristic feature of RIP1Tag2 tumors (Figures 2c-e and g), they are not connected with the blood circulation and are thought to form when vessel wall integrity is transiently disrupted during sprouting angiogenesis induced by growth factors that predispose to vascular permeability (Hashizume et al., 2000) . These lacunae were detected also in WT tumors, but were much more prominent in the BbKO tumors, where their presence was associated with a strong reduction in tumor cellularity (Figures 2c-e and g; Figures 3c and 5a). Thus, although similar in size to WT, the BbKO tumors contained much less cells. Consistent with this, cell proliferation was significantly decreased in BbKO tumors (Figure 2f ), although increased apoptosis, quantified as number of terminal transferase dUTP nick-end labeling (TUNEL)-positive cells, could not be detected (not shown). The adenoma to carcinoma ratio was significantly higher in the BbKO tumors, indicating that B-Raf signaling promotes tumor progression ( Figure 2h ).
To determine blood vessel density, sections were stained with antibodies against von Willebrand factor (vWF), a blood glycoprotein produced by endothelial cells and involved in blood clotting, or against CD31, an endothelial cell-cell adhesion molecule. Both antibodies have been used to visualize vascular structures. In contrast to the increase in hemorrhagic lacunae, blood vessel density was significantly reduced in BbKO tumors independently of their size (Figures 3a and b) . Cells positive for a-smooth muscle actin and desmin, expressed in both pericytes and myofibroblasts, lined the tumor-associated blood vessels of BbKO tumors, indicating that pericyte recruitment and maturation were not altered. Moreover, clusters of fibroblast-like, asmooth muscle actin and desmin-positive cells dissociated from vessel walls were regularly observed in WT, but not in BbKO tumors (Figure 3c ). These structures are symptomatic of vessel wall destabilization, and have been associated with reduced neural cell adhesion molecule (NCAM) expression by the tumor cells and metastasis (Xian et al., 2006) . Deposition of collagen type I, a prominent component of the RIP1Tag2 tumor stroma (Sugimoto et al., 2006) , could be observed in WT, but not BbKO tumors (Figure 3c , bottom). Thus, B-Raf ablation profoundly affects stromal components, predominantly the formation of new tumor blood vessels (angiogenesis), in RIP1Tag2 tumors.
Reduced VEGF-A expression, ERK and TGF-b signaling in B-Raf-deficient RIP1Tag2 tumors Some features described above (reduced tumor progression, large hollow spaces) are reminiscent of VEGF-Adeficient RIP1Tag2 tumors (Inoue et al., 2002) . B-Raf regulates VEGF-A synthesis during placental development and in mouse embryonic fibroblasts (GalabovaKovacs et al., 2006b) . Hence, we monitored VEGF-A expression in tumors in situ and in tumor cells in culture. In both cases, B-Raf ablation caused a significant reduction in VEGF-A protein levels (Figures 4a-d ). Yet, VEGF-A mRNA levels were indistinguishable between WT and knockout (KO) tumors and cultured b-cell lines (Figure 4e) . A similar reduction in VEGF-A protein, but not mRNA, was obtained by treating WT tumor cells with the MEK inhibitor U0126. ERK ). Hypoxia, however, is commonly not observed in RIP1Tag2 tumors (Casanovas et al., 2005) . Thus, although the exact reasons for the different behaviors of fibroblasts and b-cell tumors and lines are unknown, one simple explanation would be the exposure to different stimuli.
To assess whether the findings described above were relevant for the phenotype observed in vivo, we determined ERK phosphorylation by immunohistochemistry in normal islets and in tumors of WT and BbKO mice. At variance with the homogenous staining observed in normal islets (Figure 1c) , in WT b-cell tumors ERK phosphorylation was typically concentrated in the cells of the outer rim (Figure 5a ). This restricted distribution did not correlate with that of proliferating tumor cells and suggests that ERK phosphorylation may be under the control of stromaderived growth factors or of cell-adhesion molecules, like the IgCAMs NCAM or L1, which are expressed at the invasive tumor front and activate FGF receptor in both neurons and tumor cells (Perl et al., 1999; Cavallaro and Christofori, 2001; Gavert et al., 2005) . ERK phosphorylation was strongly reduced or absent in BbKO lesions (Figure 5a ). Together with the data in Figure 4 , these results indicate a cell-autonomous requirement of B-Raf for ERK phosphorylation and for the control of VEGF-A expression in RIP1Tag2 tumors in situ and in culture.
Phosphorylation of specific residues in the capbinding factor eIF4E (Ser209) and its inhibitor 4E-BP1 (Ser65) reportedly correlate with enhanced rates of translation (Wang et al., 2007) . eIF4E ) is a crucial component of the eIF4F complex, which facilitates the assembly of the translation initiation complex. Formation of the eIF4F complex is negatively regulated by 4E-binding proteins (4E-BPs), which in its unphosphorylated form binds to eIF4E and blocks its interaction with eIF4G, ultimately inhibiting cap-dependent translation. eIF4E is overexpressed in a wide range of human tumors and contributes to malignancy by selectively enabling the translation of a limited pool of mRNAs, notably VEGF-A (De Benedetti and Graff, 2004). Both eIF4E and 4E-BP1 can be phosphorylated as a consequence of ERK activation: eIF4E is phosphorylated by the Mnk kinases (Ueda et al., 2004) , themselves direct ERK targets (Waskiewicz et al., 1997) . The phosphorylation of 4E-BP1 is controlled by mammalian target of rapamycin, but ERK may impinge on it indirectly, through the phosphorylation and inactivation of TSC2 by the ERK target p90rsk (Roux et al., 2004) . eIF4E and 4E-BP1 were found hypophosphorylated both in BbKO tumors and in continuously growing BbKO tumor cells (Figures 5b-d) . Treatment of WT tumor cells with the MEK inhibitor U0126 similarly reduced phosphorylation of both proteins (Figure 5c and e). It is important to note here that during the angiogenic phase of RIP1Tag2 tumors, VEGF-A mRNA has been reported to decline, although protein levels are maintained constant by an unknown mechanism (Inoue et al., 2002) . The data in Figures 4 and 5 indicate that B-Raf, likely via ERKinduced phosphorylation of eIF4E and 4E-BP1, is an essential component of this mechanism (Figure 5i) .
ERK-dependent gene expression, exemplified by the target gene Egr-1, was also reduced in both BbKO (Figures 5b and d) . Several Egr-1 target genes are involved in the establishment and maintenance of tumor stroma. In particular, Egr-1 stimulates TGF-b transcription, and both the ERK pathway (Pannu et al., 2007) and Egr-1 have been implicated as central mediators of TGF-b-induced collagen deposition (Lee et al., 2004) . In line with the observed delay in tumor progression (Figure 2h ) and the reduced collagen deposition typical of BbKO tumors (Figure 3c ), levels of TGF-b mRNA were reduced in BbKO tumors in situ (Figure 5f ). TGF-b and collagen type I expression was also dramatically decreased in BbKO b-cell tumor lines (Figures 5g and h ), confirming the cell-autonomous nature of the defect. The expression of Egr-1, TGF-b and collagen type I could also be reduced by incubating continuously growing WT tumor cell lines with the MEK inhibitor U0126 (Figures 5e and g-h) confirming that ERK signaling is essential for these processes in b-cell lines. In contrast, although Egr-1 has been reported to inhibit 4E-BP1 expression in hematopoietic cell lines (Rolli-Derkinderen et al., 2003) , 4E-BP1 upregulation did not correlate with the reduced expression of Egr-1 in b-cell lines or tumors.
Although the exact relationship among ERK signaling, Egr-1 and TGF-b is still unclear and additional experiments are required to clarify this specific point, our data are consistent with a working model in which B-Raf-mediated activation of ERK supports tumorigenesis by the upregulation of factors necessary for tumor vascularization and progression (Figure 5i ) rather than by promoting cell-autonomous proliferation. Indeed, treatment with U0126 did not reduce the proliferation of b-cell lines in culture (Figure 5j) .
Mechanistically, B-Raf/ERK supports the stromal response by mediating the phosphorylation of eIF4E and 4E-BP on one hand, and the expression of Egr-1 on the other. If this model is correct, ERK activation should play a minor role, or not be implicated, in tumor proliferation.
Egr-1 can either suppress or enhance tumor development in mouse models and in humans, depending on the molecular context (Baron et al., 2005) . Egr-1's tumor suppressor function relies on its ability to induce p53 (Krones- Herzig et al., 2003 Herzig et al., , 2005 , disabled by SV40T antigen in the RIP1Tag2 model. Similarly, Egr-1 ablation delays progression of SV40 T-driven mouse prostate adenocarcinomas, without affecting tumor incidence or burden (Abdulkadir et al., 2001) . In humans, Egr-1 expression is selectively upregulated in prostate adenocarcinomas in which p53 is inactivated, and it is highest in aggressive, invasive tumors (Eid et al., 1998) . Notably, Egr-1 localizes at the tumor margin, consistent with a role in tumor invasion/ progression, and reminiscent of the pattern of B-Rafdependent ERK phosphorylation observed in the RIP1Tag2 tumors. Thus, the ERK/Egr-1 axis may be a valuable target in the large proportion of tumors in which p53 is inactivated.
Cancer cells containing activating B-Raf mutations absolutely require the ERK pathway for survival and proliferation, and are exquisitely sensitive to MEK inhibitors. B-Raf or MEK inhibitors may not, however, score positive in assays measuring the proliferation or survival of tumor cells with other mutations. For example, cells bearing an activating Ras mutation are much less responsive to these inhibitors (Solit et al., 2006) , most likely due to the complexity of the Ras pathway with its multiple branches capable of sustaining proliferation (Lim and Counter, 2005) . Interestingly, at least in melanoma cells it is Raf-1, and not B-Raf, that mediates MEK/ERK activation downstream of mutated N-Ras (Dumaz et al., 2006) . Our data show that in RIP1Tag2 tumors, in which the ERK pathway is not mutationally activated, B-Raf is the essential ERK activator. In addition, they indicate that in vivo the BRaf/MEK/ERK cascade is instrumental in the communication of the tumor with its environment, determining its capacity to recruit stromal components and blood vessels necessary for its growth and progression. Interfering with the B-Raf/MEK/ERK pathway to reduce the production of angiogenic factors might be effective, in combination with cytostatic agents, in the therapy of solid tumors that rely on an angiogenic switch for their nutrient supply.
Materials and methods
Mice and genotyping b-raf f/f (Chen et al., 2006) , Rip-Cre (Ahlgren et al., 1998) and RIP1Tag2 transgenic mice (Hanahan, 1985) have been previously described. All mice were backcrossed to 129Sv background for a minimum of seven generations. Glucose (5% w/v) was added to the drinking water of all of the tumorbearing mice, beginning at 10 weeks of age, to counteract hypoglycemia that results from insulinoma development and is ultimately responsible for the death of the animals. Animal work was done in accordance with a protocol authorized by the Austrian Ministry of Science and Communications, following the approval by the National Ethical Committee for Animal Experimentation. Tissue DNA was prepared and genotyped by PCR as described in Galabova-Kovacs et al. (2006b) .
Cell culture
Primary tumors were isolated, cultured and established as described (Efrat et al., 1988) . To determine the number of cells undergoing DNA synthesis, we used the 5-bromo-2-deoxyuridine (BrdU) proliferation assay kit (Roche, Vienna, Austria) according to the manufacturer's instructions. Briefly, the cells were labeled with 10 mM BrdU for 1 h, fixed and stained with biotin-conjugated a-BrdU mouse monoclonal antibody (1:250) and counterstained with hematoxylin. For detection, the cells were incubated with ABC (avidin-biotinylated enzyme complex) reagent (Vector Laboratories, Burlingame, CA, USA) followed by reaction with AEC (Vector Laboratories). Light microscopy was performed using an AxioImager M1 microscope equipped with a CCD camera (AxioCam Mrc5). Images were acquired using the Axiovision 4.6 software (Carl Zeiss MicroImaging Inc.) and the number of BrdU cells per mm 2 was determined using the Autmess option of the Axiovision software.
Histology, immunohistochemistry and immunofluorescence
Hematoxylin and eosin staining and immunohistochemistry were performed on 3-mm thick sections of 4% paraformaldehyde-fixed and paraffin-embedded tissues. Staining with the following antibodies was performed: a-B-Raf (H-145, Santa Cruz Biotechnology, Santa Cruz, CA, USA), a-pERK (Cell Signaling Technology, Danvers, MA, USA), a-VEGF-A (Santa Cruz Biotechnology), a-CD31 (BD Pharmingen, Schwechat, Austria), a-vWF, a-Smooth Muscle Actin (Dako, Vienna, Austria), a-Desmin (Sigma, Vienna, Austria), a-Collagen type I (Southern Biotech, Birmingham, AL, USA) and a-Ki-67 (Novo-Castra, Newcastle upon Tyne, UK). For detection, we used Alexa Fluor 488 (Molecular Probes, Lofer, Austria) and ABC (Vector Laboratories) or the DAKO EnVision peroxidase system, followed by incubation with 0.01% diaminobenzidine (Sigma) and counterstaining with hematoxylin. To quantify the number of tumors expressing different amounts of VEGF-A, we first selected prototype tumors expressing low amounts of VEGF-A (from KO sections) or medium, high and very high amounts of VEGF-A (from WT sections). Two independent investigators, blind to the identity of the sections, analysed 15 tumors from four WT and 20 tumors from four KO mice and cataloged them according to the different amounts of VEGF-A expressed. Their scores were cumulated to achieve a duplicate estimate of VEGF-A expression in WT and KO tumors. TUNEL labeling was performed according to the manufacturer's protocol (In Situ Cell Death Detection Kit, Roche) and counterstained with propidium iodide.
Immunoblot analysis
Immunoblot analysis was performed as previously described (Mikula et al., 2001) . The primary antibodies were a-B-Raf (C-19; Santa Cruz Biotechnology); a-pERK, a-4EBP1, a-p4EBP1, a-Egr-1 (Cell Signaling Technology) and MEK-2 (Transduction Laboratories, Schwechat, Austria). 
Statistical analysis
All values are expressed as means ± s.d. P-values were calculated using the unpaired two-tailed homoskedastic t-test. A P-value p0.02 is considered statistically significant.
